PraanaTech develops next‑generation ocular imaging technology that detects disease biomarkers directly in the eye. Their platform enables early diagnosis and monitoring of conditions such as Alzheimer’s disease through non‑invasive retinal scans. The solution aims to improve patient outcomes by providing clinicians with accessible, high‑resolution diagnostic data.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic imaging technologies for diseases like Alzheimer's and cancer can be expensive and inaccessible, hindering early detection and timely monitoring, particularly in resource-limited healthcare settings. This lack of accessibility can lead to delayed diagnoses and treatment, impacting patient outcomes.
Solution
PraanaTech is developing a new generation of Positron Emission Tomography (PET) imaging technology designed to be more affordable and adaptable for wider use in the diagnosis and monitoring of Alzheimer's disease and cancer. Their compact, high-resolution PET systems aim to improve the accessibility of advanced imaging, enabling earlier and more frequent monitoring of disease progression. By collaborating with hospitals, PraanaTech is actively testing its technology to refine its application in neurological diseases, oncology, and particle therapy. The goal is to provide a cost-effective solution that enhances the quality of life through improved disease management.
Target Audience
The primary target audience includes hospitals, clinics, and healthcare providers seeking affordable and accessible diagnostic imaging solutions for early detection and monitoring of Alzheimer's disease and cancer.
Features
- Compact and high-resolution PET system design.
- Adaptable systems applicable to neurological diseases, oncology, and particle therapy.
- Collaboration with hospitals for active testing and validation.